An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis

Pfizer

Status: Not yet enrolling

Conditions: Ulcerative Colitis (UC)

Treatments: Drug: Velsipity

Study type: Observational

Funder types: Industry

Identifiers

NCT07459686

C5041036

Details and patient eligibility

About

A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.

Enrollment: 553 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study. Patients who have participated in a clinical study of this drug in the past or patients who have participated in this study are excluded.
2. Patients who understand the contents of this study and give consent to provision of the information collected in this study to third parties and the use of it for other purposes.

Trial design

553 participants in 1 patient group

Patients with ulcerative colitis

Description:

Patients taking velsipity

Treatment:

Drug: Velsipity